CORT Related Analyst Ratings
-
Piper Jaffray Downgrades Corcept Therapeutics (CORT) to Neutral
-
Piper Jaffray Starts Corcept Therapeutics (CORT) at Overweight
-
Janney Montgomery Scott Starts Corcept Therapeutics (CORT) at Buy
-
Cowen Downgrades Corcept Therapeutics (CORT) to Neutral
-
Piper Jaffray Downgrades Corcept Therapeutics (CORT) to Underweight
-
Oppenheimer Downgrades Corcept Therapeutics (CORT) to Perform
-
Piper Jaffray Downgrades Corcept Therapeutics (CORT) to Neutral
-
BofA/Merrill Lynch Starts Corcept Therapeutics (CORT) at Underperform
-
ThinkEquity Starts Corcept Therapeutics (CORT) at Buy
-
Credit Suisse Starts Corcept Therapeutics (CORT) at Outperform
-
Analysts Boost Price Targets on Corcept (CORT) Following FDA Approval of Korlym
-
Leerink Swann maintains an 'Outperform' on Corcept Therapeutics (CORT); Korlym Approved. Launch To Start On May 1
-
Corcept Therapeutics (CORT) Rockets On FDA Approval; Analyst Sees Peak U.S. Sales of $300M
-
Corcept Therapeutics (CORT) Get Boost From Leerink Swann Upgrade - Positive Ahead of PDUFA Date for Korlym
-
Leerink Swann Upgrades Corcept Therapeutics (CORT) to Outperform; mproved Confidence in Commercial Outlook
-
BioLogic Equity Research Starts Corcept Therapeutics (CORT) at Sell
-
Leerink Swann Downgrades Corcept Therapeutics (CORT) to Market Perform
-
Piper Jaffray Starts Corcept Therapeutics (CORT) at Overweight, Price Target $7
-
Leerink Swann Initiates Coverage on Corcept Therapeutics (CORT) with an Outperform
-
Global Hunter Securities Initiates Coverage on Corcept Therapeutics. (CORT) with a Buy
-
Ladenburg Thalmann Upgrades Corcept Therapeutics (CORT) to Buy
-
Punk Ziegel Upgrades Corcept Therapeutics (CORT) to Accumulate
-
Merriman Curhan Downgrades Corcept Therapeutics (CORT) to Neutral
-
Merriman Curhan Starts Corcept Therapeutics Inc. (CORT) at Buy
-
CE Unterberg Starts Corcept Therapeutics (CORT) at Buy
Back to CORT Stock Lookup
